The Mironid® team enjoyed participating in the @American Society of Nephrology meeting during kidney week earlier this month, which our Chief Scientific Officer, Dr Adele Rowley, Chief Medical Officer Dr Catherine Kelleher, and Head of Biology Dr David Henderson attended. […]
Our Chief Scientific Officer @Dr Adele Rowley, Chief Medical Officer @Dr Catherine Kelleher, and Head of Biology @Dr David Henderson will be representing Mironid® at Kidney Week 2023, hosted by the American Society of Nephrology from 1-5 November in Philadelphia, Pennsylvania. […]
Read more de Attendance at American Society of Nephrology meeting
Roche Venture Fund joins existing major investors Epidarex Capital, Sofinnova Partners and BioGeneration Ventures […]
BIO-Europe convenes over 5,000 attendees, representing 60 countries and 2,220+ companies, making the event the industry’s largest gathering of biopharma professionals in Europe […]
Read more de Mironid’s CEO will be attending BioEurope in Munich, 6th-8th November 2023
Mironid® representatives will be attending the conference in Boston to discuss advances in our ADPKD program […]
For more than 20 years, Bio€quity Europe has been where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry today. […]
Read more de Mironid’s CEO will be attending BioEquity in Dublin, 14-16th May 2023
After being held digitally the last three years, BIO-Europe Spring is back in-person with an estimated record breaking 3,500+ total attendees representing over 1,400 companies and 53 countries […]
Read more de Mironid’s CEO will be attending BioEurope Spring in Basel, 28th-30th March 2023
Mironid’s CEO will be attending BioEurope in Leipzig, 24-26th October 2022’ […]
A recently published review of emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling provides positive support for Mironid’s LoAc® molecules. […]
Read more de Mironid® LoAc® mechanism of action covered in recent ADPKD review